STAT+: HHS plans funding for research into ibogaine for PTSD

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I’m plunging into psychedelia again — journalistically speaking. If you have any interesting tips on the matter, email me! Oura deal may complicate Lilly’s GLP-1 telehealth ties Eli Lilly already sends patients looking for a GLP-1 prescription to Counsel Health through its pharmacy platform LillyDirect. Now, smart ring maker Oura is buying Counsel, which could give Lilly a financial interest in a telehealth company it promotes. Lilly has agreed to buy $50 million in Oura stock if certain conditions are met, though the drugmaker says those conditions haven’t been met yet, STAT’s Elaine Chen writes. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe